North Core Life

Shenzhen North Core Life Technology Co., Ltd. ("North Core") is an industry-renowned technology enterprise that provides clinical innovative solutions for precision diagnosis and treatment of cardiovascular diseases such as coronary heart disease, atrial fibrillation, and peripheral vascular diseases. North Core's independently developed products in high-end medical technology fields such as fractional flow reserve (FFR) and intravascular ultrasound (IVUS) not only filled the gap and rewrote the situation where clinical precision diagnosis of coronary heart disease in China completely relied on imported products, but also successfully entered the Western European and Northern European markets. The innovative design and quality of the products have been highly praised by European clinical experts.

North Core has established a full value chain business covering the research and development, production, and sales of high-performance innovative medical devices, and is expected to become an enterprise that drives breakthroughs and development in China's high-performance active interventional medical device industry. North Core has a production plant of over 6,000 square meters and 3 GMP Class 10,000 clean workshops; it has built a network of about 140 distributors worldwide; North Core's FFR system has been clinically used in over 640 hospitals globally and has entered developed country markets such as Belgium, Germany, and France, with its corresponding global commercialization map still continuously expanding.

North Core's core R&D team includes returnee scientists with scientific research achievements, national and provincial innovation and entrepreneurship talents, as well as senior technical experts in the domestic medical field. Since its establishment in 2015, North Core has received nearly RMB 1 billion in investment support from globally renowned venture capital institutions such as Decheng Capital, Sequoia Capital, SDIC Unity Capital, Qiming Venture Partners, and Boyu Capital.